Difference between revisions of "Moxetumomab pasudotox (Lumoxiti)"
Jump to navigation
Jump to search
m (Jwarner moved page Moxetumomab pasudotox (HA22) to Moxetumomab pasudotox (Lumoxiti): FDA approval) |
m (→Also known as) |
||
| Line 9: | Line 9: | ||
==Also known as== | ==Also known as== | ||
| + | *'''Generic name:''' moxetumomab pasudotox-tdfk | ||
*'''Code names:''' CAT-8015, HA22 | *'''Code names:''' CAT-8015, HA22 | ||
*'''Brand name:''' Lumoxiti | *'''Brand name:''' Lumoxiti | ||
Revision as of 19:13, 13 September 2018
Mechanism of action
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)
Diseases for which it is used
History of changes in FDA indication
- 9/13/2018: Initial FDA approval "for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA)."
Also known as
- Generic name: moxetumomab pasudotox-tdfk
- Code names: CAT-8015, HA22
- Brand name: Lumoxiti